Ackman Feels 'Sad' for Michael Pearson on Forced Valeant (VRX) Sale
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant (VRX) Investors Should Be Focused on Earnings Not Upcoming Product Catalysts - Wells Fargo
July 14, 2016 1:29 PM EDTWhile Valeant Pharmaceuticals (NYSE: VRX) continues to avoid trading on fundamentals three potential catalysts lie ahead for the company. Today, Wells Fargo bearish-leaning analyst David Maris provide his thoughts ahead of these events.
The 3 events are:
Friday (7/15) advisory panel documents should become available ahead of next Tuesdays (7/19) FDA advisory panel on brodalumab;next... MoreValeant Pharma (VRX) Comments on Recent Stock Transactions by Former CEO Pearson
July 14, 2016 8:51 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) today commented on recent stock transactions made by Valeant's former chief executive officer, J. Michael Pearson. The Company understands that Mr. Pearson exercised and sold options representing approximately 4.4 million shares, which would expire within the next 12 months, and sold approximately 411,000 shares of common stock in June and July to satisfy tax obligations with respect to the 2015 margin sale conducted by Goldman Sachs, and for additional liquidity. Mr. Pearson remains a significant Valeant... More
